NCT03151486 - A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55308942 in Healthy Male and Female Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 3, 2017

Primary Completion Date

March 8, 2018

Study Completion Date

March 8, 2018

Conditions

Healthy

Interventions

DRUG

JNJ-55308942 0.5 mg

Participants will receive JNJ-55308942 0.5 mg as an oral solution after an overnight fast on Day 1.

DRUG

JNJ-55308942 1.5 mg

Participants will receive JNJ-55308942 1.5 mg as an oral solution after an overnight fast on Day 1.

DRUG

JNJ-55308942 4 mg

Participants will receive JNJ-55308942 4 mg as an oral solution after an overnight fast on Day 1.

DRUG

JNJ-55308942 12 mg

Participants will receive JNJ-55308942 12 mg as an oral solution after an overnight fast on Day 1.

DRUG

JNJ-55308942 36 mg

Participants will receive JNJ-55308942 36 mg as an oral solution after an overnight fast on Day 1.

DRUG

JNJ-55308942 100 mg

Participants will receive a single oral dose of JNJ-55308942 100 mg as an oral solution after an overnight fast on Day 1.

DRUG

JNJ-55308942: Fed State

Participants will receive JNJ-55308942 as an oral solution in fed state on Day 1. The dose selected for this cohort will be based on the data obtained from the single ascending dose cohorts.

DRUG

JNJ-55308942: MAD Part

Participants will receive JNJ-55308942 once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.

DRUG

Placebo

Participants will receive matching placebo in all cohorts.

Trial Locations (1)

2170

Clinical Pharmacology Unit, Merksem